JAK1/TYK2-IN-4 is a small molecule inhibitor that targets Janus kinases (JAKs), specifically JAK1 and TYK2, which are critical components of the signaling pathways for various cytokines and growth factors. This compound is primarily investigated for its potential therapeutic applications in autoimmune diseases and inflammatory conditions due to its ability to modulate immune responses. The chemical structure of JAK1/TYK2-IN-4 typically features specific functional groups that enhance its binding affinity and selectivity for the target kinases. Its mechanism of action involves the inhibition of JAK-mediated signal transduction, thereby reducing the activity of pro-inflammatory cytokines. In preclinical studies, it has shown promise in reducing disease symptoms and improving outcomes in models of autoimmune disorders. As with many investigational drugs, the safety profile, pharmacokinetics, and long-term effects are subjects of ongoing research. Overall, JAK1/TYK2-IN-4 represents a significant advancement in the development of targeted therapies for conditions driven by dysregulated immune responses.

JAK1/TYK2-IN-4

2734918-33-1: JAK1/TYK2-IN-4 is a small molecule inhibitor that targets Janus kinases (JAKs), specifically JAK1 and TYK2, which are critical components of the signaling pathways for various cytokines and growth factors. This compound is primarily investigated for its potential therapeutic applications in autoimmune diseases and inflammatory conditions due to its ability to modulate immune responses. The chemical structure of JAK1/TYK2-IN-4 typically features specific functional groups that enhance its binding affinity and selectivity for the target kinases. Its mechanism of action involves the inhibition of JAK-mediated signal transduction, thereby reducing the activity of pro-inflammatory cytokines. In preclinical studies, it has shown promise in reducing disease symptoms and improving outcomes in models of autoimmune disorders. As with many investigational drugs, the safety profile, pharmacokinetics, and long-term effects are subjects of ongoing research. Overall, JAK1/TYK2-IN-4 represents a significant advancement in the development of targeted therapies for conditions driven by dysregulated immune responses.

<p>JAK1/TYK2-IN-4 serves as a dual inhibitor targeting both JAK and TYK2, displaying IC50 values of 39 nM and 21 nM, respectively. It is also orally bioavailable [1].</p>

CAS 2734918-33-1

JAK1/TYK2-IN-4

JAK1/TYK2-IN-4

Ref: TM-T86755